Introduction
Since covid19 pandemic, safe and effective vaccination against it became
so important. Up to now, more than 50 vaccines against severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed in
clinical trials. Chadox1 ncov-19 (AZD1222) is one of them which has been
used in national vaccination programs against the disease in many
countries 1. Viral
infection after covid 19 vaccination have been reported. Furer et al,
has reported six cases of herpes zoster following BNT162b2 mRNA Covid-19
vaccination 2.
Herpes virus reactivation has been reported following trivalent
influenza, hepatitis A, and rabies vaccines, suggesting
vaccine-modulated immunomodulation3. To our knowledge
there were no case reports of herpes simplex infections or herpes like
skin lesions in the chadox1 ncov-19 (azd1222) vaccine clinical trials4, but some cases have
been reported in the UK spontaneous reports received between April
1st to April 14th 2021 for COVID-19
vaccine Oxford University/AstraZeneca.
In this study we are going to report a Herpes simplex virus (HSV)
reactivation following chadox1 ncov-19 (AZD1222) vaccination.